Fatty Liver Index vs. Biochemical-Anthropometric Indices: Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease with Non-Invasive Tools

被引:0
|
作者
Demirci, Selim [1 ]
Sezer, Semih [1 ]
机构
[1] Dr Abdurrahman Yurtaslan Oncol Training & Res Hosp, Dept Gastroenterol, TR-06200 Ankara, Turkiye
关键词
anthropometry; metabolic dysfunction-associated steatotic liver disease (MASLD); non-invasive diagnosis; triglyceride-glucose index; fatty liver index;
D O I
10.3390/diagnostics15050565
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a significant global burden, attributed to its increasing prevalence and strong correlation with metabolic syndrome and related conditions. Timely diagnosis and intervention are essential for minimizing the impact of MASLD. This study sought to analyze the efficacy of advanced anthropometric indices and non-invasive steatosis markers in diagnosing MASLD. Methods: This cross-sectional retrospective study evaluated the data from 578 Turkish patients admitted to our gastroenterology clinic. MASLD was diagnosed based on internationally recognized criteria. The evaluated parameters included body mass index (BMI); waist-hip ratio (WHR); waist-height ratio (WHtR); body roundness index (BRI); conicity index (CI); a body shape index (ABSI); visceral adiposity index (VAI); abdominal volume index (AVI); lipid accumulation product (LAP); fatty liver index (FLI); hepatic steatosis index (HSI); and triglyceride-glucose index (TyG) and its variants TyG-waist circumference(WC) and TyG-BMI. Results: Among 215 men, 103 (56.9%) met the criteria for MASLD, while 260 out of 363 women (65.5%) fulfilled the criteria. In the receiver operating characteristic (ROC) analysis for identifying MASLD, TyG-WC (0.826), TyG-BMI (0.820), and FLI (0.830) achieved the highest area under the curve (AUC) values, with statistically significant differences observed in their pairwise comparisons against the other parameters. Conclusions: TyG-WC and TyG-BMI are comparable to FLI in terms of simplicity of calculation and superior diagnostic accuracy, making them valuable non-invasive alternatives for MASLD screening and diagnosis.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Ultrasound Elastography-Cornerstone of Non-Invasive Metabolic Dysfunction-Associated Fatty Liver Disease Assessment
    Hari, Andrej
    MEDICINA-LITHUANIA, 2021, 57 (06):
  • [32] Nutrients associated with metabolic dysfunction-associated steatotic liver disease
    Jeong, Seogsong
    JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e81 - e82
  • [33] Vascular endothelial growth factor A, a potential non-invasive biomarker for metabolic dysfunction-associated steatotic liver disease progression
    Jonsson, Cecilia
    Ma'ayeh, Showgy
    Zhang, Boxi
    Kechagias, Stergios
    Liljeblad, Mathias
    Nasr, Patrik
    Hansson, Sara F.
    Ekstedt, Mattias
    CLINICAL BIOCHEMISTRY, 2025, 137
  • [34] Anthropometric Indices and Metabolic Dysfunction-Associated Fatty Liver Disease in Males and Females Living With Severe Obesity
    Lajeunesse-Trempe, Fannie
    Dugas, Selena
    Maltais-Payette, Ina
    Tremblay, eve-Julie
    Piche, Marie-Eve
    K. Dimitriadis, Georgios
    Lafortune, Annie
    Marceau, Simon
    Biertho, Laurent
    Tchernof, Andre
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 2025 (01)
  • [35] Association of non-invasive tests (NITs) with genetic polymorphism in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
    Younossi, Zobair
    Estep, James M.
    Zekrya, Zohal
    Felix, Sean
    Lam, Brian
    Younossi, Zaid
    Racila, Andrei
    Stepanova, Maria
    JOURNAL OF HEPATOLOGY, 2024, 80 : S572 - S573
  • [36] Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella
    Noureddin, Mazen
    Wei, Lai
    Castera, Laurent
    Tsochatzis, Emmanuel A.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (01) : 9 - 11
  • [37] Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease
    Hu, Ye
    Sun, Chao
    Chen, Ying
    Liu, Yu-Dong
    Fan, Jian-Gao
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2024, 12 (09) : 802 - 814
  • [38] Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Stefanska, Anna
    Bergmann, Katarzyna
    Suwala, Szymon
    Mankowska-Cyl, Aneta
    Kozinski, Marek
    Junik, Roman
    Krintus, Magdalena
    Panteghini, Mauro
    METABOLITES, 2024, 14 (01)
  • [39] Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
    Abdelhameed, Farah
    Kite, Chris
    Lagojda, Lukasz
    Dallaway, Alexander
    Chatha, Kamaljit Kaur
    Chaggar, Surinderjeet S.
    Dalamaga, Maria
    Kassi, Eva
    Kyrou, Ioannis
    Randeva, Harpal S.
    CURRENT OBESITY REPORTS, 2024, 13 (03): : 510 - 531
  • [40] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290